Figure 3.
A new approach for cancer immunotherapy: AAV-IL-27 enhances cancer immunity by induction of multi-functional Th1/Tc1 effector stem cells and depletion of Tregs. IL-27 also controls autoimmunity by inhibiting induction of Th17/Th2 cells and inducing IL-10 production in T cells. The limitation for induction of T cell expression of PD-L1 can be utilized for developing combination therapy.